Press Releases

Achieved Record Q2 2022 FIRDAPSE® Net Product Revenues of $53.0 Million , a 57.7% YoY Increase Cash and Short-Term Investments at June 30, 2022 were $220.8 Million , with No Funded Debt Completed Acquisition of Ruzurgi® U.S. and Mexico Commercial Rights Advanced Plans to Diversify Portfolio and

The Company Will Host a Conference Call and Webcast on August 10, 2022, at 8:30 AM ET CORAL GABLES, Fla. , July 26, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and

As Part of the Settlement, Catalyst has Acquired Certain of Jacobus’ Intellectual Property Rights, Including the U.S. and Mexico Rights to Ruzurgi® CORAL GABLES, Fla. , July 12, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage

CORAL GABLES, Fla. , May 17, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that

Achieved Record Revenues of more than $43 Million , a 42.7% Increase YoY Three New Patents Issued; Now Five Orange-Book Listed Patents for FIRDAPSE ® Significant Cash Position of $198 Million and No Funded Debt Advanced Plans to Diversify and Invest in Innovative Rare Disease Opportunities

The Company to Host a Conference Call and Webcast on May 11, 2022, at 8:30 AM ET CORAL GABLES, Fla. , April 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing

Total 2021 Revenues Increased Approximately 18% YoY to $141 Million Strong 2022 Revenue Growth Expected, Supported by FIRDAPSE ® Orphan Drug Exclusivity New Patent Issuances Strengthens FIRDAPSE Long-Term Commercial Potential to 2034 Actively Pursuing Opportunities to Diversify Commercial and

CORAL GABLES, Fla. , March 11, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare

The Company Ranked 65th of More Than 1,000 Companies Assessed CORAL GABLES, Fla. , March 08, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing

The Company Will Host a Conference Call and Webcast on March 17, 2022, at 8:30 AM ET CORAL GABLES, Fla. , March 03, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,